1. For selected reviews about diverse biological activities of dihydrobenzoxazinones, see: (a) Macías, F. A.; Marín, D.; Oliveros-Bastidasab, A.; Molinillo, J. M. G. Nat. Prod. Rep. 2009, 26, 478–489. (b) Ilaš, J.; Anderluh, P. Š.; Dolenc, M. S.; Kikelj, D. Tetrahedron 2005, 61, 7325–7348. (c) Osbourn, A. E.; Lanzotti, V. Plant-Derived Natural Products: Synthesis, Function, and Application; Springer: Heidelberg, 2009. (d) Holsworth, D.; Park, W., U.S. Patent 2009311318 (A1), Substituted (S)-benzoxazinones, Dec. 17, 2009; (e) Su, S.S. Michael, Pyruvate kinase Activators for Use for Increasing Lifetime of the Red Blood Cells and Treating Anemia Patent WO 2012151440, Nov. 8, 2012. (f) Yoon, G.; Jeong, H. J.; Kim, J. J.; Cheon, S. H. Arch. Pharm. Res. 2008, 31, 989–994.
2. Relay Iron/Chiral Brønsted Acid Catalysis: Enantioselective Hydrogenation of Benzoxazinones
3. Dynamic kinetic resolution of α-chloro esters in asymmetric nucleophilic substitution using diacetone-D-glucose as a chiral auxiliary
4. Stereoselective SN2 Reactions of the (R)-Pantolactone Ester of Racemic .alpha.-Halo Carboxylic Acids with Aryl Oxides. A Synthesis of (S)-2-Aryloxy and (S)-2-Hydroxy Acids
5. In references 3 and 4, it was established that (αS)-products were provided in the substitution of both 1 and 2 with various amine nucleophiles. The absolute configuration of 3–14 is assigned by analogy. The S configuration of (S)-3 was confirmed after the conversion to 8 using H2 with Pd/C, by the comparison of chiral stationary phase-HPLC retention times and elution order with the reported values of 8 in ref. 2. ref. 2a-d.